In conclusion, regardless of whether it functions as a classical oncogene or a CSC-specific regulator, novel anti-cancer therapeutic strategies will emerge from further research on the molecular mechanisms of EZH2 action in CSC regulation. This evidence concerns the gene EZH2 and cancer.